India, April 30 -- Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 16.67 million shares at a price of $18.00 per share. The gross proceeds to Avalyn are expected to be $300 million.
The shares are expected to begin trading on the Nasdaq Global Select Market on April 30, 2026, under the ticker symbol "AVLN."
In addition, Avalyn has granted the underwriters a 30-day option to buy an additional 2.50 million shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
The offering is expected to close on May 1, 2026, subject to customary closing conditions.
Morgan Stanley, Jefferies, Evercore ISI and Guggen...